Premium On-Demand Presentations - 24/7keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Premium On-Demand Presentations - 24/7 - JST (Japan Standard Time, GMT+9)
keyboard_arrow_leftSearch & Filter
search
Topics
Premium On-Demand Presentations - 24/7 - JST (Japan Standard Time, GMT+9)
search
Topics
Premium On-Demand Presentations - 24/7
On Demand
Minimizing Deviation from Fully Human Germline Antibody Sequences During Affinity Maturation
- Andre Frenzel, PhD - Founder and CSO, Yumab
On Demand
Dual Specificity PD-L1/PD-L2 Antibodies Treat Both Immune “Hot” and “Cold” Cancers
- Michael Curran, Ph.D. - Associate Professor, Department of Immunology, The UT MD Anderson Cancer Center
On Demand
REGN4018 is a Mucin 16 Bispecific T cell–engaging Antibody for the Treatment of Ovarian Cancer
- Alison Crawford, PhD - Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals
On Demand
Systems Engineering to Design More Effective Monoclonal Therapeutics
- Galit Alter, Ph.D. - Professor of Medicine, Harvard Medical School and Group Leader, Ragon Institute of MGH, MIT and Harvard
On Demand
The Structural Role of N-Glycosylation in interactions between Antibodies and Receptors
- Adam Barb, Ph.D. - Associate Professor, Biochemistry and Molecular Bi, University of Georgia
On Demand
Human Monoclonal Antibodies for SARS-CoV-2
- James Crowe, Jr., M.D. - Director, Vanderbilt Vaccine Center, Vanderbilt University Medical Center
On Demand
Affinity Maturation of Therapeutic Antibodies Using Mammalian Cell Display Coupled with in vitro Somatic Hypermutation Mimics Natural Maturation
- Stephen Parmley, Ph.D. - Vice President, Molecular Biology & Protein Science, AnaptysBio
On Demand
Effective Engagement of TNFR-SF Members by Antibody Approaches
- Denise Faustman, M.D., Ph.D. - Associate Professor of Medicine, Harvard Medical School
On Demand
Bispecific Antibody T cell-engagers
- Michael Hedvat, Ph.D. - Group Leader, Cell Biology, Xencor
On Demand
Engineered Fc-glycosylation Switch to Eliminate Antibody Effector Function
- Anna Park, Ph.D. - Distinguished Scientist, Head of Protein Engineering, Sanofi
On Demand
Antibodies Against Malaria: Structural Insights into Parasite Inhibition
- Jean-Philippe Julien, Ph.D. - Senior Scientist, Molecular Medicine, Hospital for Sick Children Research Inst
On Demand
Broadly Neutralizing Antibodies to Speed Pandemic Responses
- Laura Walker, Ph.D - Associate Director, Adimab, LLC.
On Demand
Biophysical Properties of Human B cell-derived Antibodies
- Laura Walker, Ph.D - Associate Director, Adimab, LLC.
On Demand
Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy
- Thomas Schürpf, Ph.D. - Associate Director, Discovery Biology, Scholar Rock, Inc
On Demand
Engineering Bispecific Antibodies as Therapeutics: Utilizing Intrinsic Heavy/Light Chain Pairing Preferences and Mitigating High Viscosity
- Paul Carter, PhD - Genentech Fellow, Department of Antibody Engineering, Genentech, Inc.
On Demand
The Precise Humanization of Immunoglobulin Constants and High and Low Affinity hFcγRs to Replicate Human Antibody Effector Function in Mice
- Faith Harris - Senior R&D Specialist, Regeneron
On Demand
Anti-idiotypic Antibodies against Germline Versions of HIV-1 Broadly Neutralizing Antibodies
- Marie Pancera, Ph.D. - Principal Staff Scientist Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center
On Demand
Recombinant Immunotoxins Produce anti-tumor Immunity
- Ira Pastan, M.D. - Co-Chief, National Cancer Institute
On Demand
Using E.coli to Identify Aggregation Propensity in Therapeutic and Disease-causing Proteins
- David Brockwell, PhD - Associate Professor, University of Leeds
On Demand
Human-derived Antiviral Antibodies - Accelerating Antibody Discovery Timelines
- Christoph Esslinger, Ph.D. - CSO, Memo Therapeutics
On Demand
Engineered Avibodies (enhanced Diabodies) Precisely Loaded with Novel ADC Payloads that Surpass IgG-ADCs in Cancer Therapy
- Peter Hudson - Head of Technology and Innovation, Sepura
On Demand
Probody Therapeutics in the Treatment of Cancer
- Marcia Belvin, Ph.D. - SVP, Research, CytomX Therapeutics
On Demand
The Structural Basis of Neutralization by Antibodies Against Viral Fusion Proteins
- Pamela Bjorkman, Ph.D. - David Baltimore Professor of Biology and Biologica, Caltech
On Demand
scFv Meets Fab: New Switchable CAR-Ts
- Christoph Rader - Professor, Department of Immunology and Microbiology, The Scripps Research Institute
On Demand
Using Multiplexed Flow Cytometry to ScreenAntibodies and Sera
- Fridtjof Lund-Johansen - Senior Scientist, Oslo University Hospital, Rikshospitalet
Premium On-Demand Presentations - 24/7 10:30 - 11:0030 mins
A Novel Therapeutic Antibody Targeting Human Osteoprotegerin Attenuates Severe Experimental Pulmonary Arterial Hypertension
- Allan Lawrie, Ph.D. - Professor of Translational Cardiopulmonary Science, University of Sheffield Medical School
On Demand
A Coiled-Coil Masking Domain for Selective Activation of Therapeutic Antibodies
- Matthew Levengood, Ph.D. - Principal Scientist, Protein Sciences, Seattle Genetics
On Demand
Novel Tumor Selective anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor Microenvironment
- Mika Kamata-Sakurai, Ph.D. - Senior Director, Translational Research Division, Chugai Pharmaceutical Co., Ltd.
On Demand
Using Single-cell Transcriptomics to Identify Broadly Neutralizing Antibodies against Flaviviruses
- Leslie Goo, Ph.D. - Assistant Professor Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center
On Demand
Massively Multiplexed and Quantitative Characterization of Antibody-antigen Interactions
- David Younger, Ph.D. - Co-Founder & CEO, A-Alpha Bio
On Demand
NGM621: A Potent Inhibitory anti-Complement C3 Antibody for Treatment of Geographic Atrophy
- Jie Tang, PhD - Senior Director of Protein Science, NGM Biopharmaceuticals
On Demand
Antibody Fragment Drug Conjugates (FDCs) a Tailored Solution for Solid Tumours
On Demand
XTENylated Protease Activated T cell Engagers: XPATS - A Novel Format to Mitigate the On-target, Off-tumor Problem
- Volker Schellenberger, Ph.D. - President and CTO, Amunix Pharmaceuticals
On Demand
Two Tales of Targeting MerTK
- Yan Wu, PhD - Director and Staff Scientist, Antibody Engineering, Genentech
On Demand
Cellular Screening Platforms for Engineering T cell Receptors and Chimeric Antigen Receptors
- Sai Reddy, PhD - Associate Professor, Department of Biosystems Science and Engineering at ETH Zurich, ETH Zurich
On Demand
Engineering Novel Conditionally Activated Immune Therapeutics to Fight Cancer
- William Winston, Ph.D. - Vice President, Research, Werewolf Therapeutics
On Demand
Innovative Therapeutics for Severe COVID-19 and ARDS by Combining ACE2-Fc with a Potent Complement Inhibitor
- Bo Yu - Co-founder and Chief Scientific Officer, Larix Bioscience LLC
On Demand
TCR Engineering
On Demand
From the Trenches of Antibody De Novo Design: Lessons Learned
- Monica Berrondo, PhD - CEO, Macromoltek
On Demand
Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting
- Theodore Roth - MD/PhD Student, UCSF, USA
On Demand
Antibodies Exhibit Multiple Paratope States that Can Differ in VH-VL Domain Orientations
- Klaus Liedl, Ph.D. - Professor, University of Innsbruck
On Demand
Designer Cytokines for Targeted Immune Modulation
- Jamie Spangler, Ph.D. - Assistant Professor, Johns Hopkins University
On Demand
Programming Abs: AI-based Design of Clever Antibodies that Bind Multiple Targets within a Single Binding Site
- Yanay Ofran, Ph.D. - Chief Executive Officer, Biolojic Design
On Demand
Therapeutic Targeting of a Novel NK- and T-cell Immune Checkpoint
- Carl Uli Bialucha - VP Drug Discovery, Immunitas Therapeutics
On Demand
Antibodies against SARS-CoV-2: A Global Consortium
- Erica Ollmann Saphire, Ph.D. - Professor, La Jolla Institute for Immunology
On Demand
Anti-GITR Antibody Development
- Taha Merghoub, Ph.D. - Assistant Attending Lab Member, Memorial Sloan Kettering Cancer Center
On Demand
Predicting Antibody Structures to High-resolution with Deep Learning Approaches
- Jeffrey Gray, Ph.D. - Professor, Chemical & Biochemical Engineering, Johns Hopkins University
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Topics